Suchergebnisse - "Trimarchi, Hernán"

PubPharm (117)

1

Capacity for the management of kidney failure in the International Society of Nephrology Latin America region : report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA)

enthalten in: Kidney international supplements | 2024

von Calice-Silva, V. | Neyra, J. | Ferreiro Fuentes, A. | +77

CommentIn: Kidney Int Suppl (2011). 2024 Apr;13(1):1-5. - PMID 38619132

2

Targeting APRIL in the Treatment of IgA Nephropathy

enthalten in: Clinical journal of the American Society of Nephrology : CJASN | 2024

von Cheung, C. | Barratt, J. | Carroll, K. | +9

3

Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy

enthalten in: Kidney international | 2024

von Zhang, H. | Rizk, D. | Perkovic, V. | +13

4

Points of view in nephrology : personalized management of IgA nephropathy, beyond KDIGO

enthalten in: Journal of nephrology | 2024

von Trimarchi, H. | Fervenza, F. | Coppo, R.

5

Human parietal epithelial cells (PECs) and proteinuria in lupus nephritis : a role for ClC-5, megalin, and cubilin?

enthalten in: Journal of nephrology | 2023

von Ceol, M. | Gianesello, L. | Trimarchi, H. | +8

6

Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis

enthalten in: The New England journal of medicine | 2023

von Rheault, M. | Alpers, C. | Barratt, J. | +125

CommentIn: N Engl J Med. 2024 Mar 21;390(12):1153-1154. - PMID 38507767

7

Clinical Practice Patterns in IgA Nephropathy : A Global Questionnaire-Based Survey

enthalten in: Kidney international reports | 2023

von Bansal, B. | Grewal, A. | Teo, B. | +8

8

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT) : 2-year results from a randomised, active-controlled, phase 3 trial

enthalten in: Lancet (London, England) | 2023

von Rovin, B. | Barratt, J. | Heerspink, H. | +130

CommentIn: Lancet. 2023 Dec 2;402(10417):2046-2047. - PMID 37931627

9

Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd) : 2-year results from a randomised phase 3 trial

enthalten in: Lancet (London, England) | 2023

von Lafayette, R. | Kristensen, J. | Stone, A. | +10

CommentIn: Lancet. 2023 Sep 9;402(10405):827-829. - PMID 37591290

10

Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy

enthalten in: Nature genetics | 2023

von Kiryluk, K. | Sanchez-Rodriguez, E. | Zhou, X. | +98

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[12]